Skip to main content
Elanix Biotechnologies AG logo

Elanix Biotechnologies AG — Investor Relations & Filings

Ticker · ELN ISIN · DE000A0WMJQ4 LEI · 391200SYNFFL0NPAJK90 F Manufacturing
Open in API
Filings indexed 161 across all filing types
Latest filing 2017-04-26 Report Publication Anno…
Country DE Germany
Listing F ELN

About Elanix Biotechnologies AG

https://elanixbiotechnologies.com/

Elanix Biotechnologies AG is a tissue regeneration company that develops and commercializes products for acute wound care, dermatological, and gynecological applications. The company's core focus is on creating therapeutic solutions derived from progenitor cells. Its product development pipeline aims to provide advanced treatments for skin and tissue repair.

Recent filings

Filing Released Lang Actions
Report Publication Announcement 2017
Report Publication Announcement Classification · 100% confidence The document is extremely short (1800 characters) and its sole purpose is to announce that specific financial reports (Annual financial report and Annual financial report of the group) will be disclosed on a future date (April 28, 2017). It explicitly states 'Elanix Biotechnologies AG hereby announces that the following financial reports shall be disclosed'. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report will be published or is attached classifies the document as a Report Publication Announcement (RPA), not the report itself (like 10-K or IR).
2017-04-26 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German securities law (WpHG). It reports changes in voting rights percentages (crossing thresholds) for a specific shareholder (Mr David Lukas Deck) in Elanix Biotechnologies AG. This directly corresponds to the definition of a major shareholding notification, which in the provided schema is best matched by 'Major Shareholding Notification' (MRQ), as it details changes in significant ownership levels crossing thresholds. Although the header mentions 'Voting Rights Announcements', the content structure aligns perfectly with a major holding disclosure.
2017-04-24 English
Elanix Biotechnologies AG: Restatement gem. IAS 8 im Rahmen des Konzernabschlusses 2016 geplant/Vorlaufige, ungeprufte Konzernzahlen zum Geschaftsjahr 2016 und Ausblick
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc' announcement dated April 15, 2017, from Elanix Biotechnologies AG. It explicitly states it is an 'Insiderinformation gemäß Artikel 17 MAR' (Insider Information according to Article 17 MAR) and publishes 'Vorläufige, ungeprüfte Konzernzahlen zum Geschäftsjahr 2016' (Preliminary, unaudited group figures for the 2016 financial year) along with an outlook and details about a planned restatement (IAS 8). This content—preliminary, unaudited results for a period—is the core characteristic of an Earnings Release (ER). Although it mentions the final audited figures will be announced later, the immediate release of preliminary results and key performance indicators (EBITDA, EBIT) classifies it as the initial results announcement. FY 2016
2017-04-15 German
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Resulting situation' and 'Previous notification' of voting rights percentages, referencing German securities law (WpHG). This directly corresponds to the definition of a notification of changes in significant share ownership levels or voting rights, which aligns best with the 'Major Shareholding Notification' (MRQ) category. Although the header mentions 'Voting Rights Announcements', MRQ is the specific code for tracking changes in ownership thresholds.
2017-03-22 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains sections detailing 'Notification of Major Holdings', 'Reason for notification' (specifically 'Change of breakdown of voting rights'), and 'Total positions' regarding voting rights percentages. This content directly corresponds to regulatory filings concerning changes in significant share ownership or voting power, which aligns with the definition for Declaration of Voting Results & Voting Rights Announcements (DVA) or Major Shareholding Notification (MRQ). Since the primary focus is the change in voting rights structure due to an acquisition/disposal, and the header explicitly mentions 'Voting Rights Announcements', DVA is the most precise fit, although MRQ is also closely related. Given the options, DVA covers the announcement of voting rights changes explicitly.
2017-03-17 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG). It details changes in voting rights percentages (from 4.98% to 2.46%) held by a specific person (Mr Gilbert Schöni) in Elanix Biotechnologies AG. This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership thresholds. The appropriate code is MRQ.
2017-03-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.